Experts Found No Reasons to Restrict DMPA

Apn Cnp Diane E. Judge

In: Journal watch · 2009 · vol. 2009 · doi:10.1056/wh200904160000003 · W2280625445

article OA: closed CC0

View on OpenAlex View at publisher

Abstract

The association between depot medroxyprogesterone acetate (DMPA) and loss of BMD led the U.S. FDA and Health Canada to issue warnings about this

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health 2009

References (1)

The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health via openalex

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK